ACUTE VULVOVAGINAL CANDIDIASIS TREATMENT MARKET ANALYSIS

Acute Vulvovaginal Candidiasis Treatment Market, by Drug Type (Clotrimazole, Nystatin, Fluconazole, Ketoconazole, Terbinafine, Terconazole, and Others), by Route of Administration (Oral, Intravenous, and Topical), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

Published In : Dec 2020
Code : CMI4315
Pages :152
Formats :
Excel and PDF
Industry : Pharmaceutical

Leading Companies

Companies covered:

Mycovia Pharmaceuticals, Inc., Scynexis, Inc., Basilea Pharmaceutica Ltd., Astellas Pharma Inc., Grupo Ferrer Internacional, S.A., Pacgen Life Science Corporation, NovaDigm Therapeutics, Inc., Cidara Therapeutics, Inc., Amplyx Pharmaceuticals Inc., and Pfizer, Inc.

Global Acute Vulvovaginal Candidiasis Treatment Market – Competitive Landscape

Major players operating in the global acute vulvovaginal candidiasis treatment market include Mycovia Pharmaceuticals, Inc., Scynexis, Inc., Basilea Pharmaceutica Ltd., Astellas Pharma Inc., Grupo Ferrer Internacional, S.A., Pacgen Life Science Corporation, NovaDigm Therapeutics, Inc., Cidara Therapeutics, Inc., Amplyx Pharmaceuticals Inc., and Pfizer, Inc.